Laser Immunotherapy: A Potential Treatment Modality for Keratinocyte Carcinoma

par Silje Haukali Omland, Emily Cathrine Wenande, Inge Marie Svane, Joshua Tam, Uffe Høgh Olesen, Merete Hædersdal
Publié 2021

Natural CD4+ T-cell responses against indoleamine 2,3-dioxygenase.

par Shamaila Munir, Stine Kiaer Larsen, Trine Zeeberg Iversen, Marco Donia, Tobias Wirenfeldt Klausen, Inge Marie Svane, Per Thor Straten, Mads Hald Andersen
Publié 2012

Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model

par Henrik Jespersen, Mattias F. Lindberg, Marco Donia, Elin M. V. Söderberg, Rikke Andersen, Ulrich Keller, Lars Ny, Inge Marie Svane, Lisa M. Nilsson, Jonas A. Nilsson
Publié 2017

Author Correction: Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma

par Martin Lauss, Marco Donia, Katja Harbst, Rikke Andersen, Shamik Mitra, Frida Rosengren, Maryem Salim, Johan Vallon-Christersson, Therese Törngren, Anders Kvist, Markus Ringnér, Inge Marie Svane, Göran Jönsson
Publié 2020

Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma

par Martin Lauss, Marco Donia, Katja Harbst, Rikke Andersen, Shamik Mitra, Frida Rosengren, Maryem Salim, Johan Vallon-Christersson, Therese Törngren, Anders Kvist, Markus Ringnér, Inge Marie Svane, Göran Jönsson
Publié 2017

The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase.

par Rikke Baek Sørensen, Linda Berge-Hansen, Niels Junker, Christina Aaen Hansen, Sine Reker Hadrup, Ton N M Schumacher, Inge Marie Svane, Jürgen C Becker, Per thor Straten, Mads Hald Andersen
Publié 2009

Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A R...

par Morten Fink, Anders Schwartz Vittrup, Lars Bastholt, Inge Marie Svane, Marco Donia, Adam A. Luczak, Christina H. Ruhlmann, Louise Mahncke Guldbrandt, Ulrich Heide Koehler, Mette Lerche Winther, Eva Ellebaek, Charlotte Aaquist Haslund, Henrik Schmidt
Publié 2021

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types

par Marco Donia, Troels Holz Borch, Özcan Met, Julie Westerlin Kjeldsen, Morten Nielsen, Inge Marie Svane, Anders Handrup Kverneland, Christopher Aled Chamberlain, Sofie Kirial Mørk, Cathrine Lund Lorentzen, Lise Pyndt Jørgensen, Lene Buhl Riis, Christina Westmose Yde
Publié 2021

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

par Antoni Ribas, Inge Marie Svane, Paolo Antonio Ascierto, Victoria Atkinson, Razi Ghori, Anna Maria Di Giacomo, Georgina V Long, Henrik Schmidt, Jacob Schachter, Eduard Gasal, Paola Queirolo, Michal Lotem, Michele Del Vecchio, Pier Francesco Ferrucci, Rosalie Stephens, Mahmoud Abu-Amna, Scott J Diede, Elizabeth S Croydon
Publié 2020

Escape from nonsense-mediated decay associates with anti-tumor immunogenicity

par Kevin Litchfield, James L. Reading, Emilia L. Lim, Hang Xu, Po Liu, Maise Al-Bakir, Yien Ning Sophia Wong, Andrew Rowan, Samuel A. Funt, Taha Merghoub, David Perkins, Martin Lauss, Inge Marie Svane, Göran Jönsson, Javier Herrero, James Larkin, Sergio A. Quezada, Matthew D. Hellmann, Samra Turajlic, Charles Swanton
Publié 2020